Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Gut Microbiota–Related Biomarkers in Immuno-Oncology

Open access
Silva, Carolina Alves Costa, Fidelle, Marine, Almonte, Andrew A., Derosa, Lisa, Zitvogel, Laurence · 2025 · Annual Review of Pharmacology and Toxicology

Abstract

Carcinogenesis is associated with the emergence of protracted intestinal dysbiosis and metabolic changes. Increasing evidence shows that gut microbiota-related biomarkers and microbiota-centered interventions are promising strategies to overcome resistance to immunotherapy. However, current standard methods for evaluating gut microbiota composition are cost- and time-consuming. The development of routine diagnostic tools for intestinal barrier alterations and dysbiosis constitutes a critical unmet medical need that can guide routine treatment and microbiota-centered intervention decisions in patients with cancer. In this review, we explore the influence of gut microbiota on cancer immunotherapy and highlight gut-associated biomarkers that have the potential to be transformed into simple diagnostic tools, thus guiding standard treatment decisions in the field of immuno-oncology. Mechanistic insights toward leveraging the complex relationship between cancer immunosurveillance, gut microbiota, and metabolism open exciting opportunities for developing novel biomarkers in immuno-oncology.

Overview

Integrity signals

Registry

Crossref · 10.1146/annurev-pharmtox-061124-102218

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

1 retracted

Show all 137 references

Research works printed but not linked: 4

  1. 2022, Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC), Ann. Oncol., 33, 1452MO
  2. 2016, Biomarkers of gut barrier failure in the ICU, Curr. Opin. Crit. Care, 22, 152
  3. 2023, Association of circulating markers of gut barrier damage and inflammation with colorectal neoplasia stage, Cancer Res, 83, 5544
  4. 2013, METABOLOMICSSTANDARD—Metabolomics: defining the standards for sample preparation of small molecules

Cited by

See all 22

Metadata

Authors
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L.
Affiliations
Inserm (FR)
Venue
Annual Review of Pharmacology and Toxicology
Published
2025-01-23
Volume
65
Issue
1
Pages
333-354
ISSN
  • 0362-1642 (ISSN-L)
  • 1545-4304
OpenAlex
W4402432767
Cited by
22
References
137
Citations by year
2026: 10 · 2025: 11
FWCI
0.90
Type
journal article
Language
en
Open access
Locations
  • The Annual Review of Pharmacology and Toxicology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • theses.fr (ABES) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
Funders
Agence Nationale de la Recherche (ANR-21-RHUS-0017, ANR-18-IDEX-0001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut microbiota, biomarkers, cancer immunotherapy, immunotherapy resistance, gut dysbiosis, intestinal barrier, tumor surveillance, cancer metabolism, diagnostic tools, carcinogenesis
MeSH terms
Gastrointestinal Microbiome, Animals, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Biomarkers, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut Microbiota–Related Biomarkers in Immuno-Oncology. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-061124-102218
The paper
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025). Gut Microbiota–Related Biomarkers in Immuno-Oncology. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-061124-102218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.